Treatment of Ph-like ALL is challenging, thus B-ALL with CRLF2 overexpression and/or IKZF1 deletion are often resistant to conventional treatment, and have an increased incidence of relapse and poor prognosis [31–33]. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.